

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**ESPS manuscript NO:** 30858

**Title:** Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective

**Reviewer's code:** 02769486

**Reviewer's country:** United Kingdom

**Science editor:** Jing Yu

**Date sent for review:** 2016-10-21 09:15

**Date reviewed:** 2016-11-02 21:20

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

## COMMENTS TO AUTHORS

I enjoyed reading this review and would like to compliment the authors on a comprehensive and interesting review of the literature. However, in my opinion, there was one very important omission in the section on combination therapy; namely the combination of low dose azathioprine with allopurinol (LDAA). Given that not all countries can use or are able to afford monoclonal therapy, and I would expect clinicians from all over the world would read this article, I think it is imperative that this issue is discussed. Albeit not a popular therapeutic option the arguments for and against should be addressed, given this is "Current evidence..." and LDAA is being prescribed up front in some centres. I am sure the authors will be aware of the literature about LDAA, however there are two very recent articles (one which has only just become available on PubMed) that I would strongly advise careful consideration for inclusion into this review: Scand J Gastroenterol. 2016 Dec;51(12):1470-1475. Epub 2016 Aug 10. Randomized clinical trial: a pilot study comparing efficacy of low-dose azathioprine and allopurinol to azathioprine on clinical outcomes in inflammatory bowel disease. Kiszka-Kanowitz M1, Theede K, Mertz-Nielsen A., and Inflamm Bowel Dis. 2016



## BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

---

Jul;22(7):1639-46. doi: 10.1097/MIB.0000000000000827. Long-term Safety and Efficacy of Low-dose Azathioprine and Allopurinol Cotherapy in Inflammatory Bowel Disease: A Large Observational Study. Pavlidis P, Stamoulos P, Abdulrehman A, Kerr P, Bull C, Duley J, Ansari A. With this in mind the conclusion should also acknowledge that combination of low dose azathioprine with allopurinol may become a more widespread treatment option particularly in countries where expensive monoclonal and other new therapies are not an option. One minor point, on page 15 second paragraph the units after 235 have been omitted.

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**ESPS manuscript NO:** 30858

**Title:** Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective

**Reviewer's code:** 03535116

**Reviewer's country:** Turkey

**Science editor:** Jing Yu

**Date sent for review:** 2016-10-21 09:15

**Date reviewed:** 2016-10-31 19:52

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

## COMMENTS TO AUTHORS

October 31, 2016 Dear Author, Axelrad and coworkers have reviewed Thiopurines and inflammatory bowel disease— Current evidence and a historical perspective. Overall it's a good study, detailed comments that need author's attention are given below: In "Introduction section", the chemical structure of compounds should be given for each compound used for inflammatory bowel disease. Thiopurines and their metabolites should be explained as reaction scheme in "Thiopurine drug metabolism and blood level monitoring" section. In "Abstract section" to replace "anti-TNF" with "anti-tumor necrosis factor (anti-TNF)". "Thiopurine Indication" and "Evidence and dose" given in Table 1 should be noted that the names of thiopurines. Sincerely,